Abstract:In February 2018, the World Health Organization (WHO) proposed 10 viral diseases of zoonoses to be priority research and development, 8 of which are transmitted by aerosols or in close contact with humans, and 2 are transmitted directly or indirectly by mosquito vectors. Beside the Zika virus, 9 highly pathogenic viruses are required to operate in high level biosafety laboratories(BSL), of which 6 need to be in BSL-4, 3 in BSL-3. Therefore, research and development of these viruses can only be undertaken in conditional laboratories. In this paper, the transmission route, clinical harm and the main direction and status of vaccine development of these 10 kinds of virus diseases are briefly described, and the prevention and control problems of these infectious diseases are discussed and analyzed in order to make proper preparations for prevention and control of these infectious diseases.
严延生. 需优先发展防控手段的10种人兽共患病毒病[J]. 中国人兽共患病学报, 2019, 35(3): 185-195.
YAN Yan-sheng. Ten viral zoonoses diseases requiring priority development methods for prevention and control. Chinese Journal of Zoonoses, 2019, 35(3): 185-195.
[1] WHO.Essential medicines and health products .[EB/OL][2018-12-03].https://www.who.int/medicines/ebola-treatment/ebola_documents/en/ [2] Mehand MS, Al-Shorbaji F, Millett P, et al. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts[J]. Antiviral Res,2018,159:63-67. DOI: 10.1016/j.antiviral.2018.09.009 [3] Leblebicioglu H. Crimean-Congo haemorrhagic fever in Eurasia[J]. Int J Antimicrobial Agents 2010,36(Suppl 1):S43-6. [4] Vorou R, Pierroutsakos IN, Maltezou HC. Crimean-Congo hemorrhagic fever[J]. Curr Opin Infect Dis 2007;20:495-500. [5] 中华人民共和国卫生部.人间传染的病原微生物名录[EB/OL].(2006-01-12)[2018-12-03].http://www.chinacdc.cn/n272442/n272530/n3479265/n3479284/20774.html [6] Dowall SD, Carroll M W, Hewson R. Development of vaccines against Crimean-Congo haemorrhagic fever virus[J].Vaccine,2017. 35:6015-6023 [7] Papa A, Papadimitriou E, Christova I. The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain[J]. Scandinavian J Infect Dis ,2011,43:225-9. [8] Christova I, Kovacheva O, Greorgieva G, et al. Vaccine against Congo-Crimean haemorhagic fever virus-Bulgarian input in fighting the disease[J]. Probl Infect Parasit Dis, 2010,37:7-8. [9] WHO. WHO experts consultation on Ebola Reston pathogenicity in humans. Emergencies preparedness, response[R/OL]. [2009-04-01](2019-01-02). http://www.who.int/csr/resources/publications/WHO_HSE_EPR_2009_2/en/ [10] WHO. Ebola Situation Report - 30 March 2016. Ebola virus disease outbreak[R/OL]. [2016-05-30](2019-01-02).http://apps.who.int/ebola/current-situation/ebola-situation-report-30-march-2016 [11] Baize S, Pannetier D, Oestereich L,et al. Emergence of Zaire Ebola virus disease in Guinea[J]. N Engl J Med,2014, 371:1418-1425. [12] Medaglini D, Siegrist CA. Immunomonitoring of human responses to the rVSVZEBOV Ebola vaccine[J]. Curr. Opin. Virol. (2017)23 88-94, DOI:10.1016/j.coviro.2017.03.008 [13] Stanley DA, Honko AN, Asiedu C, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge[J]. Nat Med,2014,20:1126-9. [14] Kennedy SB, Bolay F, Kieh M, et al. PREVAIL I Study Group, Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia[J]. N Engl J Med,2017,377:438-1447, DOI:10.1056/NEJMoa1614067 [15] Medaglini, D, Santoro F, Siegrist CA. Correlates of vaccine-induced protective immunity against Ebola virus disease [J]. Seminars in Immunology, 2018,DOI:10.1016/j.smim.2018.07.003 [16] Brauburger K, Hume AJ, Mühlberge E,et al. Forty-Five Years of Marburg Virus Research[J]. Viruses, 2012, 4:1878-1927. DOI:10.3390/v4101878 [17] Zehender G, Sorrentino C, Veo C, et al. Distribution of Marburg virus in Africa: An evolutionary approach[J]. Infect Genet Evol,2016,44:8-16. DOI: 10.1016/j.meegid.2016.06.014 [18] Geisbert TW, Bausch DG, Feldmann H.Prospects for immunization against Marburg and Ebola viruses[J]. Rev Med Virol, 2010,20: 344-357. DOI:10.1002/rmv.661 [19] Mire CE, Geisbert JB, Agans KN, et al. Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates[J]. PLoS ONE, 2014, 4: e94355. DOI:10.1371/journal.pone.0094355 [20] Frame JD, Baldwin JM, Gocke DJ,et al. Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings[J]. Am J Trop Med Hyg,1970, 19(4):670-676. [21] Safronetz D, Strong JE, Feldmann F, et al. A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques[J]. J Infect Dis,2013,207(8):1316-1327. [22] Raoul J. de Groot,a Susan C, et al. Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group[J]. J Virology,2013, 87(14): 7790-7792 [23] Shin N, Kwag T, Park S, et al. Effects of operational decisions on the diffusion of epidemic disease: A system dynamics modeling of the MERS-CoV outbreak in South Korea[J]. J Theor Biol,2017,421:39-50. DOI: 10.1016/j.jtbi.2017.03.020. Epub 2017 Mar 27. [24] 武桂珍.中东呼吸综合征(MERS-CoV)实验室生物安全[EB/OL](2015-06-12)[2019-01-02].https://wenku.baidu.com/view/47fd47416137ee06eef9187c.html [25] Modjarrad K.MERS-CoV vaccine candidates in development:The current landscape[J]. Vaccine,2016, 34:2982-2987 [26] Clayton BA . Nipah virus: transmission of a zoonotic paramyxovirus[J]. Curr Opin Virol,2017,22:97-104. DOI: 10.1016/j.coviro.2016.12.003. [27] Pulliam JRC, Epstein J H, Dushoff J, et al. Agricultural intensification, priming for persistence and the emergence of Nipah virus: a lethal bat-borne zoonosis[J]. J R Soc Interface,2012, 9, 89-101. doi:10.1098/rsif.2011.0223 [28] Prescott J, DeBuysscher BL, Feldmann F, et al. Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects african green monkeys from nipah virus disease[J].Vaccine,2015,33(24): 2823-2829. DOI:10.1016/j.vaccine.2015.03.089 [29] Murray K, Rogers R, Selvey RL, et al. A novel morbillivirus pneumonia of horses and its transmission to humans[J]. Emerg Infect Dis, 1995, 1(1): 31-33. DOI: 10.3201/eid0101.950107 [30] Murray K, Selleck P, Hooper P.A morbillivirus that caused fatal disease in horses and humanse[J]. Scienc,1995, 268, 94-97. [31] WHO. Emergencies: Hendra Virus (HeV) Infection [EB/OL][2019-01-03]https://www.who.int/emergencies/diseases/hendra-virus/en/ [32] WIKIPEDIA. Henipavirus[EB/OL].[2018-12-03].https://en.wikipedia.org/wiki/Henipavirus#Hendra_virus [33] Smith I, Broos A, Jong CD. Et al. Identifying hendra virus diversity in pteropid bats[J]. PLoS ONE, 2011, 6: e25275. [34] Pallistera J, Middletona D, Wanga LF, et al. A recombinant hendra virus G glycoprotein-based subunit vaccine protects ferrets from Lethal Hendra virus Challenge[J]. Vaccine,2011, 29(34):5623-5630. DOI: 10.1016/j.vaccine.2011.06.015. Epub 2011 Jul 1 [35] Middleton D, Pallister J, Klein R, et al. Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health[J]. Emerg Infect Dis,2014,20:372-379. [36] Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome[J]. N Engl J Med,2003,348(20):1967-76 [37] World Health Organization. Summary tables of SARS cases by country, 1 November 2002-7 August 2003[J]. Weekly Epidemiological Record,2003,78(35):310. [38] Smith I, Wang LF. Bats and their virome: an important source of emerging viruses capable of infecting humans[J]. Curr Opin Virol,2013, 3:84-91. [39] Wang LF, Shi ZL, Zhang SY,et al. Review of bats and SARS[J]. Emerg Infect Dis,2006, 12:1834-1840. [40] Raj VS,Mou H,Smits SL et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC[J]. Nature,2013, 495:251-254. [41] Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J]. Nature. 2003,426(6965):450-454. [42] Graham RL,Donaldson EF,Baric RS,et al. A decade after SARS: Strategies to control emerging coronaviruses[J]. Nat Rev Microbiol, 2013, 11(12): 836-848. DOI:10.1038/nrmicro3143. [43] Jouan A. Coulibaly I. Adam F. et al. Analytical study of a Rift Valley fever epidemic[J]. Res Virol, 1989, 140: 175-186. [44] Sow A, Faye O,Ba Y,et al. Rift Valley fever outbreak, southern Mauritania, 2012[J]. Emerg Infect Dis, 2014,20: 296-299. DOI:10.3201/eid2002.131000 [45] Sow A, Faye O, Faye O,et al. Rift Valley fever in Kedougou, southeastern Senegal, 2012[J]. Emerg Infect Dis, 2014, 20(3): 504-506. DOI: 10.3201/eid2003.131174 [46] Faburay B, LaBeaud AD, McVey S. Current status of Rift Valley Fever vaccine development[J]. Vaccines,2017, 5: 29. DOI:10.3390/vaccines5030029 [47] Saluzzo JF,Smith JF. Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine[J]. Vaccine, 1990, 8:369-375. [48] Vialat P, Muller R,Vu TH. Et al. Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation[J]. Virus Res, 1997,52: 43-50. [49] Morrill JC, Peters CJ. Mucosal immunization of Rhesus macaques with Rift Valley fever MP-12 vaccine[J]. J Infect Dis, 2011, 204: 617-625. [50] Morrill JC,Laughlin RC, Lokugamage N,et al. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep[J]. Vaccine, 2013, 31: 559-565. [51] Wikan N, Smith DR. Zika virus: history of a newly emerging arbovirus[J]. Lancet Infect Dis. 2016, 16:e119-126. [52] Lanciotti RS, Kosoy OL, Laven JJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007[J]. Emerg Infect Dis,2008,14:1232-1239. [53] Duffy MR, Chen TH, Hancock WT, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia[J]. N Engl J Med,2009,360:2536-2543. [54] Aubry M, Finke J, Teissier A, et al. Seroprevalence of arboviruses among blood donors in French Polynesia, 2011-2013[J]. Int J Infect Dis,2015,41:11-12. [55] Cao-Lormeau VM, Roche C, Teissier A, et al. Zika virus, French polynesia, South pacific, 2013[J]. Emerg Infect Dis, 2014,20:1085-1086. [56] Alera MT, Hermann L, Tac-An IA, et al. Zika virus infection, Philippines, 2012 [J].Emerg Infect Dis,2015,21:722-724. [57] Heang V, Yasuda CY, Sovann L, et al. Zika virus infection, Cambodia, 2010[J]. Emerg Infect Dis,2012,18:349-351. [58] Lednicky J, Beau De Rochars VM, El Badry M, et al. Zika virus outbreak in Haiti in 2014: molecular and clinical data[J]. PLoS Negl Trop Dis,2016,10:e0004687. [59] Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study[J]. Lancet, 2016,387:1531-1539. [60] Campos GS, Bandeira AC, Sardi SI. Zika virus outbreak, Bahia, Brazil[J]. Emerg Infect Dis ,2015, 21:1885-1886. [61] Lessler J, Chaisson LH, Kucirka LM, et al. Assessing the global threat from Zika virus[J]. Science, 2016,353(6300):aa8160. DOI:10.1126/science.aaf8160 [62] Kleber de Oliveira W, Cortez-Escalante J, De Oliveira WT, et al. Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed zika virus transmission during the first trimester of pregnancy-Brazil, 2015[J]. MMWR Morb Mortal Wkly Rep, 2016,65:242-247. [63] Rasmussen SA, Jamieson DJ, Honein MA, et al. Zika virus and birth defects-reviewing the evidence for causality[J]. N Engl J Med,2016,374:1981-1987. [64] Mysorekar IU, Diamond MS. Modeling Zika virus infection in pregnancy[J]. N Engl J Med,2016, 375(5):481-484. DOI: 10.1056/NEJMcibr1605445. [65] Brooks JT, Friedman A, Kachur RE, et al. Update: Interim guidance for prevention of sexual transmission of Zika virus-United States, July 2016[J]. MMWR Morb Mortal Wkly Rep, 2016,65:745-747. [66] D’Ortenzio E, Matheron S, Yazdanpanah Y, et al. Evidence of sexual transmission of Zika virus[J]. N Engl J Med,2016,374:2195-2198. [67] Jampol LM, Goldstein DA. Zika virus infection and the eye[J]. JAMA Ophthalmol,2016,DOI: 10.1001/jamaophthalmol.2016.0284. [68] 中华人民共和国教育部.国家卫生计生委办公厅关于进一步加强寨卡(Zika)病毒和H5N6流感病毒实验室生物安全管理工作的通知[EB/OL][2018-12-03] http://www.moe.edu.cn/s78/A16/s8213/A16_gggs/201602/t20160224_230348.html [69] Veronica S, Kumar CV, Popli RK, et al. The emergence of zika virus as a global health security threat: A review and a consensus statement of the INDUSEM Joint working Group (JWG)[J].J global Infect Dis, 2016.8(1):3-15. DOI:10.4103/0974-777X.176140 [70] World Health Organization. Zika situation report [EB/OL][2018-12-03].https://www.who.int/emergencies/zika-virus/situation-report/en/ [71] Garg H, Tugba MG, Joshi A. Recent advances in Zika virus vaccines[J]. Viruses, 2018,10:631. DOI:10.3390/v10110631